The predictive variables assessed were age at EGPA diagnosis, baseline eosinophil count, history of chronic sinusitis prior to diagnosis, and glucocorticoid-treated asthma at diagnosis.

People with allergic fungal rhinosinusitis taking Dupixent saw significant improvement in congestion and sinus inflammation, ...

In today’s Healthy Minute, Dr. Kian Azimian will be discussing the differences between a sinus infection and seasonal ...

The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate ...

Doctors in Central Texas share the latest on flu strains, RSV, stomach viruses and cedar pollen as cold and allergy season ...

The approval makes Dupixent the first FDA-approved therapy for allergic fungal rhinosinusitis, supported by Phase III data showing significant improvements in sinus opacification, nasal symptoms, and ...

The FDA granted approval to dupilumab for treating patients aged 6 years and up with allergic fungal rhinosinusitis and a history of sino-nasal surgery, marking the first treatment approved for this ...

Facial swelling can stem from allergies, infections, sinus issues or underlying disease.

Dupixent (dupilumab) is now FDA-approved for adults and children aged 6 years and older with allergic fungal rhinosinusitis and prior sino-nasal surgery.

Pharmacists have a seen a marked increase in patients turning to them for treatment for seven of the most common health ...

Delhi-NCR is witnessing a surge in H3N2 influenza cases, with nearly 70% of households reporting flu-like symptoms. The virus ...